IO Biotech, Inc. — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IO Biotech, Inc. (IOBT)
CIK: 0001865494
Period of Report: 2021-11-09

Reporting Person: Lundbeckfond Invest A/S (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-09	Common Stock	C	2014161	—	Acquired	2014161	Direct
2021-11-09	Common Stock	C	1892434	—	Acquired	3906595	Direct
2021-11-09	Common Stock	P	2142857	$14	Acquired	6049452	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-09	Series B Preferred Stock	$	C	219595	Disposed		Common Stock (2014161)	Direct
2021-11-09	Series C Preferred Stock	$	C	150534	Disposed		Common Stock (1892434)	Direct

Footnotes

F1: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.

F2: Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.